(G) Genpact - Overview
Exchange: NYSE •
Country: Bermuda •
Currency: USD •
Type: Common Stock •
ISIN: BMG3922B1072
Stock: Business Process Outsourcing, Information Technology, Consulting, Analytics
Total Rating 44
Risk 85
Buy Signal -0.12
| Risk 5d forecast | |
|---|---|
| Volatility | 34.4% |
| Relative Tail Risk | -16.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.59 |
| Alpha | -40.85 |
| Character TTM | |
|---|---|
| Beta | 0.839 |
| Beta Downside | 1.330 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.64% |
| CAGR/Max DD | -0.07 |
EPS (Earnings per Share)
Revenue
Description: G Genpact March 04, 2026
Genpact Limited (G) is a business process outsourcing (BPO) and information technology (IT) services provider. The company operates globally, with significant presence in India, North America, and Europe. BPO services involve delegating non-primary business activities to a third-party provider.
Genpacts business is segmented into Financial Services, Consumer and Healthcare, and High Tech and Manufacturing. The Financial Services segment offers a broad range of services including loan operations, compliance, and wealth management. The Consumer and Healthcare segment focuses on areas like supply chain management, customer experience, and claims processing. The High Tech and Manufacturing segment provides solutions for trust and safety, advertising support, and engineering services. These segments demonstrate the diverse application of BPO across various industries.
The company also provides cross-industry services such as digital operations, data-tech-AI, CFO advisory, and supply chain management. This broad service portfolio is characteristic of larger BPO firms aiming to offer comprehensive solutions. Further research on ValueRay can provide deeper insights into Genpacts market position and financial performance.
Headlines to watch out for
- Financial services demand drives revenue growth
- Healthcare segment expansion boosts top-line performance
- Technology and manufacturing sector spending impacts service demand
- Global economic conditions influence outsourcing budgets
- Regulatory changes in financial services affect compliance offerings
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 552.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 1.85 > 1.0 |
| NWC/Revenue: 20.75% < 20% (prev 23.42%; Δ -2.67% < -1%) |
| CFO/TA 0.14 > 3% & CFO 812.9m > Net Income 552.5m |
| Net Debt (910.7m) to EBITDA (860.5m): 1.06 < 3 |
| Current Ratio: 1.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (175.0m) vs 12m ago -3.02% < -2% |
| Gross Margin: 36.04% > 18% (prev 0.35%; Δ 3.57k% > 0.5%) |
| Asset Turnover: 93.81% > 50% (prev 95.59%; Δ -1.78% > 0%) |
| Interest Coverage Ratio: 11.92 > 6 (EBITDA TTM 860.5m / Interest Expense TTM 65.4m) |
Altman Z'' 3.10
| A: 0.18 (Total Current Assets 2.66b - Total Current Liabilities 1.60b) / Total Assets 5.84b |
| B: 0.24 (Retained Earnings 1.39b / Total Assets 5.84b) |
| C: 0.14 (EBIT TTM 779.7m / Avg Total Assets 5.42b) |
| D: 0.16 (Book Value of Equity 530.4m / Total Liabilities 3.29b) |
| Altman-Z'' Score: 3.10 = A |
Beneish M -3.08
| DSRI: 0.98 (Receivables 1.28b/1.23b, Revenue 5.08b/4.77b) |
| GMI: 0.98 (GM 36.04% / 35.45%) |
| AQI: 0.96 (AQ_t 0.48 / AQ_t-1 0.50) |
| SGI: 1.07 (Revenue 5.08b / 4.77b) |
| TATA: -0.04 (NI 552.5m - CFO 812.9m) / TA 5.84b) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of G shares?
As of March 15, 2026, the stock is trading at USD 38.75 with a total of 2,063,639 shares traded.
Over the past week, the price has changed by -8.15%, over one month by +2.52%, over three months by -19.11% and over the past year by -21.49%.
Over the past week, the price has changed by -8.15%, over one month by +2.52%, over three months by -19.11% and over the past year by -21.49%.
Is G a buy, sell or hold?
Genpact has received a consensus analysts rating of 3.91.
Therefore, it is recommended to buy G.
- StrongBuy: 4
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the G price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.6 | 25.5% |
| Analysts Target Price | 48.6 | 25.5% |
G Fundamental Data Overview March 10, 2026
P/E Trailing = 13.3227
P/E Forward = 18.315
P/S = 1.4153
P/B = 2.7862
P/EG = 1.1623
Revenue TTM = 5.08b USD
EBIT TTM = 779.7m USD
EBITDA TTM = 860.5m USD
Long Term Debt = 1.20b USD (from longTermDebt, last quarter)
Short Term Debt = 437.7m USD (from shortTermDebt, last quarter)
Debt = 1.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 910.7m USD (from netDebt column, last quarter)
Enterprise Value = 8.31b USD (7.19b + Debt 1.76b - CCE 648.2m)
Interest Coverage Ratio = 11.92 (Ebit TTM 779.7m / Interest Expense TTM 65.4m)
EV/FCF = 11.35x (Enterprise Value 8.31b / FCF TTM 731.7m)
FCF Yield = 8.81% (FCF TTM 731.7m / Enterprise Value 8.31b)
FCF Margin = 14.40% (FCF TTM 731.7m / Revenue TTM 5.08b)
Net Margin = 10.88% (Net Income TTM 552.5m / Revenue TTM 5.08b)
Gross Margin = 36.04% ((Revenue TTM 5.08b - Cost of Revenue TTM 3.25b) / Revenue TTM)
Gross Margin QoQ = 36.56% (prev 36.37%)
Tobins Q-Ratio = 1.42 (Enterprise Value 8.31b / Total Assets 5.84b)
Interest Expense / Debt = 0.67% (Interest Expense 11.9m / Debt 1.76b)
Taxrate = 24.22% (45.7m / 188.8m)
NOPAT = 590.9m (EBIT 779.7m * (1 - 24.22%))
Current Ratio = 1.66 (Total Current Assets 2.66b / Total Current Liabilities 1.60b)
Debt / Equity = 0.69 (Debt 1.76b / totalStockholderEquity, last quarter 2.55b)
Debt / EBITDA = 1.06 (Net Debt 910.7m / EBITDA 860.5m)
Debt / FCF = 1.24 (Net Debt 910.7m / FCF TTM 731.7m)
Total Stockholder Equity = 2.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.20% (Net Income 552.5m / Total Assets 5.84b)
RoE = 21.81% (Net Income TTM 552.5m / Total Stockholder Equity 2.53b)
RoCE = 20.91% (EBIT 779.7m / Capital Employed (Equity 2.53b + L.T.Debt 1.20b))
RoIC = 15.69% (NOPAT 590.9m / Invested Capital 3.77b)
WACC = 7.34% (E(7.19b)/V(8.95b) * Re(9.01%) + D(1.76b)/V(8.95b) * Rd(0.67%) * (1-Tc(0.24)))
Discount Rate = 9.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.31%
[DCF] Terminal Value 83.01% ; FCFF base≈651.8m ; Y1≈775.7m ; Y5≈1.22b
[DCF] Fair Price = 134.7 (EV 23.86b - Net Debt 910.7m = Equity 22.95b / Shares 170.3m; r=7.34% [WACC]; 5y FCF grow 20.27% → 2.90% )
EPS Correlation: 89.48 | EPS CAGR: 13.67% | SUE: 1.23 | # QB: 6
Revenue Correlation: 95.97 | Revenue CAGR: 5.78% | SUE: 1.47 | # QB: 3
EPS next Quarter (2026-06-30): EPS=0.97 | Chg7d=+0.023 | Chg30d=+0.023 | Revisions Net=+7 | Analysts=11
EPS current Year (2026-12-31): EPS=4.02 | Chg7d=+0.066 | Chg30d=+0.066 | Revisions Net=+9 | Growth EPS=+10.1% | Growth Revenue=+7.1%
EPS next Year (2027-12-31): EPS=4.44 | Chg7d=+0.033 | Chg30d=+0.033 | Revisions Net=+5 | Growth EPS=+10.5% | Growth Revenue=+7.3%
[Analyst] Revisions Ratio: +0.78 (8 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.5% (Discount Rate 9.0% - Earnings Yield 7.5%)
[Growth] Growth Spread = +5.5% (Analyst 7.0% - Implied 1.5%)
P/E Forward = 18.315
P/S = 1.4153
P/B = 2.7862
P/EG = 1.1623
Revenue TTM = 5.08b USD
EBIT TTM = 779.7m USD
EBITDA TTM = 860.5m USD
Long Term Debt = 1.20b USD (from longTermDebt, last quarter)
Short Term Debt = 437.7m USD (from shortTermDebt, last quarter)
Debt = 1.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 910.7m USD (from netDebt column, last quarter)
Enterprise Value = 8.31b USD (7.19b + Debt 1.76b - CCE 648.2m)
Interest Coverage Ratio = 11.92 (Ebit TTM 779.7m / Interest Expense TTM 65.4m)
EV/FCF = 11.35x (Enterprise Value 8.31b / FCF TTM 731.7m)
FCF Yield = 8.81% (FCF TTM 731.7m / Enterprise Value 8.31b)
FCF Margin = 14.40% (FCF TTM 731.7m / Revenue TTM 5.08b)
Net Margin = 10.88% (Net Income TTM 552.5m / Revenue TTM 5.08b)
Gross Margin = 36.04% ((Revenue TTM 5.08b - Cost of Revenue TTM 3.25b) / Revenue TTM)
Gross Margin QoQ = 36.56% (prev 36.37%)
Tobins Q-Ratio = 1.42 (Enterprise Value 8.31b / Total Assets 5.84b)
Interest Expense / Debt = 0.67% (Interest Expense 11.9m / Debt 1.76b)
Taxrate = 24.22% (45.7m / 188.8m)
NOPAT = 590.9m (EBIT 779.7m * (1 - 24.22%))
Current Ratio = 1.66 (Total Current Assets 2.66b / Total Current Liabilities 1.60b)
Debt / Equity = 0.69 (Debt 1.76b / totalStockholderEquity, last quarter 2.55b)
Debt / EBITDA = 1.06 (Net Debt 910.7m / EBITDA 860.5m)
Debt / FCF = 1.24 (Net Debt 910.7m / FCF TTM 731.7m)
Total Stockholder Equity = 2.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.20% (Net Income 552.5m / Total Assets 5.84b)
RoE = 21.81% (Net Income TTM 552.5m / Total Stockholder Equity 2.53b)
RoCE = 20.91% (EBIT 779.7m / Capital Employed (Equity 2.53b + L.T.Debt 1.20b))
RoIC = 15.69% (NOPAT 590.9m / Invested Capital 3.77b)
WACC = 7.34% (E(7.19b)/V(8.95b) * Re(9.01%) + D(1.76b)/V(8.95b) * Rd(0.67%) * (1-Tc(0.24)))
Discount Rate = 9.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.31%
[DCF] Terminal Value 83.01% ; FCFF base≈651.8m ; Y1≈775.7m ; Y5≈1.22b
[DCF] Fair Price = 134.7 (EV 23.86b - Net Debt 910.7m = Equity 22.95b / Shares 170.3m; r=7.34% [WACC]; 5y FCF grow 20.27% → 2.90% )
EPS Correlation: 89.48 | EPS CAGR: 13.67% | SUE: 1.23 | # QB: 6
Revenue Correlation: 95.97 | Revenue CAGR: 5.78% | SUE: 1.47 | # QB: 3
EPS next Quarter (2026-06-30): EPS=0.97 | Chg7d=+0.023 | Chg30d=+0.023 | Revisions Net=+7 | Analysts=11
EPS current Year (2026-12-31): EPS=4.02 | Chg7d=+0.066 | Chg30d=+0.066 | Revisions Net=+9 | Growth EPS=+10.1% | Growth Revenue=+7.1%
EPS next Year (2027-12-31): EPS=4.44 | Chg7d=+0.033 | Chg30d=+0.033 | Revisions Net=+5 | Growth EPS=+10.5% | Growth Revenue=+7.3%
[Analyst] Revisions Ratio: +0.78 (8 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.5% (Discount Rate 9.0% - Earnings Yield 7.5%)
[Growth] Growth Spread = +5.5% (Analyst 7.0% - Implied 1.5%)